{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:05:34Z","timestamp":1787241934901,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhltopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHLT Open"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jhlto.2024.100131","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T03:33:34Z","timestamp":1721705614000},"page":"100131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil"],"prefix":"10.1016","volume":"6","author":[{"given":"Aparna C.","family":"Swaminathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Meservey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishan","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Krasuski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan W.","family":"Whitson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Dahhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Rei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Almeida-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshan","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhlto.2024.100131_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00831-2019","article-title":"Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures","volume":"54","author":"Wang","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100131_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02310-2017","article-title":"Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension","volume":"51","author":"Hjalmarsson","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100131_bib3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","article-title":"Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum","volume":"68","author":"Opitz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhlto.2024.100131_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1378\/chest.13-1900","article-title":"Causes of pulmonary hypertension in the elderly","volume":"146","author":"Pugh","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100131_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100131_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"Vachiery","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100131_bib7","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/ehf2.13804","article-title":"Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres","volume":"9","author":"Wissm\u00fcller","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jhlto.2024.100131_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1378\/chest.11-3241","article-title":"Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis","volume":"144","author":"Poms","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100131_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.chest.2018.05.006","article-title":"Association between BMI and obesity with survival in pulmonary arterial hypertension","volume":"154","author":"Weatherald","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100131_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/675994","article-title":"Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension","volume":"4","author":"Benson","year":"2014","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100131_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhlto.2024.100131_bib12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhlto.2024.100131_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhlto.2024.100131_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1086\/681264","article-title":"Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers","volume":"5","author":"Trammell","year":"2015","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100131_bib15","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.2147\/COPD.S141798","article-title":"Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension","volume":"12","author":"Wang","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jhlto.2024.100131_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/FJC.0000000000000357","article-title":"Safety and tolerability of high-dose inhaled treprostinil in pulmonary hypertension","volume":"67","author":"Parikh","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jhlto.2024.100131_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00408-017-0081-7","article-title":"Inhaled treprostinil in pulmonary hypertension associated with lung disease","volume":"196","author":"Faria-Urbina","year":"2018","journal-title":"Lung"},{"key":"10.1016\/j.jhlto.2024.100131_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/689291","article-title":"The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease","volume":"7","author":"Bajwa","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100131_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachi\u00e9ry","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100131_bib20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2022.05.038","article-title":"Clinical characteristics and transplant-free survival across the spectrum of pulmonary vascular disease","volume":"80","author":"Hemnes","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl K","key":"10.1016\/j.jhlto.2024.100131_bib21","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1093\/eurheartj\/suz205","article-title":"The burden of comorbidities in pulmonary arterial hypertension","volume":"21","author":"Lang","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jhlto.2024.100131_bib22","first-page":"101","article-title":"Inhaled treprostinil vs iloprost: comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension","volume":"29","author":"Burger","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jhlto.2024.100131_bib23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.healun.2017.02.016","article-title":"The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups","volume":"36","author":"Gall","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jhlto.2024.100131_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.003973","article-title":"Increasing incidence and prevalence of World Health Organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada","volume":"11","author":"Wijeratne","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["JHLT Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133424000806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133424000806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:27:28Z","timestamp":1753230448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950133424000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":24,"alternative-id":["S2950133424000806"],"URL":"https:\/\/doi.org\/10.1016\/j.jhlto.2024.100131","relation":{},"ISSN":["2950-1334"],"issn-type":[{"value":"2950-1334","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil","name":"articletitle","label":"Article Title"},{"value":"JHLT Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhlto.2024.100131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}],"article-number":"100131"}}